Semaglutide GLP-1 is a clinically proven treatment for obese patients with a BMI of 30 or greater or a BMI of at least 27 with comorbidities related to weight
Severe gastrointestinal disorders, such as gastroparesis
Pre-treatment assessment should include: BMI calculation and confirmation of eligibility criteria (BMI 30 kg/m or 27 kg/m with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia) Medical history review , including thyroid disease, pancreatitis, gallbladder disease, and cardiovascular risk factors Current medications , particularly antidiabetic agents that may require dose adjustment Pregnancy status and contraception counselling where relevant (Wegovy should not be used during pregnancy and should be discontinued at least 2 months before planned conception) [12] [13] Baseline investigations : HbA1c (if diabetic or at risk), lipid profile, liver function tests, and thyroid function tests as clinically indicated Discussion of realistic expectations : Wegovy is most effective when combined with lifestyle modifications, not as monotherapy Dosing schedule follows a gradual escalation protocol to minimise gastrointestinal side effects: Weeks 14: 0.25 mg once weekly Weeks 58: 0.5 mg once weekly Weeks 912: 1 mg once weekly Weeks 1316: 1.7 mg once weekly Week 17 onwards: 2.4 mg once weekly (maintenance dose) If patients experience intolerable side effects, the dose escalation may be delayed
Others feel consistent suppression throughout the week
These additions may support energy levels, metabolism, or overall well-being during the weight loss process
